Maze Therapeutics, Inc. Common Stock (MAZE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $22.66 (-3.33%), Market cap $1.39B, 52-week low–high $10.01 ~ $51.84.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease
Financial statements, price targets, institutional (13F) holdings and related news for Maze Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Maze Therapeutics, Inc. Common Stock trades at $22.66 (-3.33%). Real-time quotes and charts are available on BlackAll Trade.
Maze Therapeutics, Inc. Common Stock has a market cap of about $1.39B.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead progr